Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias

Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology

(2021) Nicholas J. Ashton et al.   ACTA NEUROPATHOLOGICA

Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia

(2020) Shorena Janelidze et al.   NATURE MEDICINE

Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts

(2020) Thomas K Karikari et al.   LANCET NEUROLOGY

Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification

(2020) Nicolas R. Barthélemy et al.   Alzheimers Research & Therapy

Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline

(2020) Juan Lantero Rodriguez et al.   ACTA NEUROPATHOLOGICA

Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study

(2020) Juan Fortea et al.   LANCET

Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases

(2020) Giovanni Palermo et al.   MOLECULAR NEUROBIOLOGY

Differential levels of Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders

(2020) C. Delaby et al.   Scientific Reports

Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative

(2020) Thomas K. Karikari et al.   MOLECULAR PSYCHIATRY

Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease

(2020) Shorena Janelidze et al.   JAMA Neurology

Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease

(2019) Oliver Preische et al.   NATURE MEDICINE

Neurofilament light chain as a biomarker in neurological disorders

(2019) Lorenzo Gaetani et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer’s disease

(2019) Estrella Morenas-Rodríguez et al.   Scientific Reports

Establishment of neurofilament light chain Simoa assay in cerebrospinal fluid and blood

(2019) Robert Hendricks et al.   Bioanalysis

Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse

(2019) Daniel Alcolea et al.   Annals of Clinical and Translational Neurology

Detection of amyloid beta peptides in body fluids for the diagnosis of alzheimer’s disease: Where do we stand?

(2019) Bhavana Veerabhadrappa et al.   CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES

Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography

(2018) Michelle M. Mielke et al.   Alzheimers & Dementia

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

(2018) Clifford R. Jack et al.   Alzheimers & Dementia

High performance plasma amyloid-β biomarkers for Alzheimer’s disease

(2018) Akinori Nakamura et al.   NATURE

Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A Multicenter Study in Spain

(2018) Daniel Alcolea et al.   JOURNAL OF ALZHEIMERS DISEASE

Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study

(2018) Juan Fortea et al.   LANCET NEUROLOGY

Impact of CSF storage volume on the analysis of Alzheimer's disease biomarkers on an automated platform

(2018) Constance Delaby et al.   CLINICA CHIMICA ACTA

An UHPLC–MS/MS method for simultaneous quantification of human amyloid beta peptides Aβ1-38, Aβ1-40 and Aβ1-42 in cerebrospinal fluid using micro-elution solid phase extraction

(2017) Ping-ping Lin et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Serum neurofilament light in familial Alzheimer disease

(2017) Philip S.J. Weston et al.   NEUROLOGY

Blood-based NfL

(2017) Oskar Hansson et al.   NEUROLOGY

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

(2014) Bruno Dubois et al.   LANCET NEUROLOGY

Quantitative immunocapture MS: current status and challenges in drug discovery

(2014) John Kellie et al.   Bioanalysis

Impact of harmonization of collection tubes on Alzheimer's disease diagnosis

(2013) Sylvain Lehmann et al.   Alzheimers & Dementia

Plasma tau levels in Alzheimer's disease

(2013) Henrik Zetterberg et al.   Alzheimers Research & Therapy

Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: an update

(2012) Marta del Campo et al.   Biomarkers in Medicine

The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Marilyn S. Albert et al.   Alzheimers & Dementia